LY2811376 is a potent and selective inhibitor of beta-secretase 1 (BACE1), an enzyme critical for the cleavage of amyloid precursor protein (APP) and subsequent production of amyloid-beta peptides. It is primarily used in research to investigate Alzheimer's disease pathology by reducing amyloid-beta accumulation in cellular and animal models. Studies have explored its ability to penetrate the blood-brain barrier, positioning it as a candidate for central nervous system (CNS) therapeutics. Additionally, it is employed in preclinical evaluations to assess impacts on amyloid processing, neuronal viability, and cognitive outcomes in neurodegenerative disease models.